Development of Equine Anthrax Antitoxin for Disease Treatment-An In vivo A/J Mice Passive Protection Assay for Evaluation of Antitoxin Potency

Hui-Fen Hsu ； Li-Jeng Tarn ； Hsueh-Ling Wu ； Hsin-Hsien Huang ； Kuo-Ching Chen ； Meng-Hung Tsai

《Journal of Medical Sciences》 33卷5期 (2013/10) Pp. 263-270

https://doi.org/10.6136/JMS.2013.33(5).263

並列摘要

Background: Anthrax Immune Globulin (AIG) is a polyclonal anthrax immunoglobulin product developed by Cangene (Winnipeg, Canada) and Emergent BioSolutions (Rockville, MD). It is derived from plasma of individuals who have been vaccinated with BioThrax (TM). It is a candidate for intravenous post-exposure treatment in patients with symptoms of anthrax disease. This study used the equine antitoxin as an alternative for anthrax medical counter measure. Methods: Horses were immunized intramuscularly with AVA (Anthrax vaccine adsorbed; BioThrax (TM) ). The sera were examined with anti-PA (Protective Antigen) ELISA and TNA (Anthrax toxin neutralization assay). The passive protection test was performed with ATCC 14186 strain spores and equine sera in A/J mice model. Results: The sera from horses immunized with AVA have high titer in anti-PA ELISA, and stable neutralization activity in TNA in vitro. In a well-controlled A/J mice animal model, the serum repeatedly and accurately protects A/J mice from exposure to a lethal challenge of the ATCC 14186 strain of Bacillus anthracis. Conclusions: Anthrax equine antitoxin shows a high titer and high neutralization activity, both in vitro and in vivo.

並列關鍵字

anthrax ； equine ； antitoxin ； A/J mice ； passive protection

參考文獻

Webb GF. Being prepared: modeling the response to an anthrax attack. Ann Intern Med 2005;142:667- 668.

Wills B, Leikin J, Rhee J, Saeedi B. Analysis of suspicious powders following the post 9/11 anthrax scare. J Med Toxicol 2008;4:93-95.

Abboud N, Casadevall A. Immunogenicity of Bacillus anthracis protective antigen domains and efficacy of elicited antibody responses depend on host genetic background. Clin Vaccine Immunol 2008;15:1115- 1123. doi: 10.1128/CVI.00015-08.

Brey RN. Molecular basis for improved anthrax vaccines. Adv Drug Deliv Rev 2005;57:1266-1292.

Marano N, Plikaytis BD, Martin SW, Rose C, Semenova VA, Martin SK, Freeman AE, Li H, Mulligan MJ, Parker SD, Babcock J, Keitel W, El Sahly H, Poland GA, Jacobson RM, Keyserling HL, Soroka SD, Fox SP, Stamper JL, McNeil MM, Perkins BA, Messonnier N, Quinn CP; Anthrax Vaccine Research Program Working Group. Effects of a reduced dose schedule and intramuscular administration of anthrax vaccine adsorbed on immunogenicity and safety at 7 months: a randomized trial. JAMA 2008;300:1532- 43. doi: 10.1001/jama.300.13.1532.